In addition, monitoring of white blood cell counts, renal function ... no skin tumors, no lymph nodes or visceral involvement IB: >10% body surface area involved, otherwise same as IB IIA ...

Because patients with mycosis fungoides have an impaired epidermal ... no skin tumors, no lymph nodes or visceral involvement IB: >10% body surface area involved, otherwise same as IB IIA: skin ...

In the study, 69 patients with cutaneous T-cell lymphoma, including the most common subtypes mycosis fungoides and Sézary syndrome, were given DD-cxdl for five consecutive days every 21 days.

A fusion protein therapy may be an effective treatment option for cutaneous T-cell lymphomas, according to a multicenter clinical trial published in the Journal of Clinical Oncology.

The next donor recruitment drives for the Marshall's Match campaign are being held this weekend - with one taking place at ...

therapy for up to 12 months in patients with early-stage cutaneous T-cell lymphoma was provided by Soligenix, Inc. · In June 2024: Innate Pharma SA released encouraging results from the Phase 2 ...

Quality of life in patients with mycosis fungoides and Sézary syndrome: a systematic review of the literature. J Eur Acad Dermatol Venereol 2021; 35: 2377-87. 15. Demierre MF, Gan S, Jones J, Miller ...

Drug coverage for four drugs used to treat some rare diseases was announced in Fredericton on Wednesday under a $32-million ...

In Canada, 1 in 12 people live with a rare disease, and for most people affected, the cost of treatment is unaffordable.  Canadians deserve a health care system that provides timely access to quality ...

Drug coverage for four drugs used to treat some rare diseases was announced in Fredericton on Wednesday under a $32 million deal signed by the federal and provincial governments. Under the ...